Interleukin-17 inhibitors in myasthenia gravis: really bad or maybe good?

作者信息

Kim Sohyeon, Eun Mi-Yeon, Seok Hung Youl

机构信息

Department of Neurology, Dongsan Hospital, Keimyung University School of Medicine, 1035 Dalgubeol-Daero, Dalseo-Gu, Daegu, 42601, Korea.

Department of Neurology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea.

出版信息

Neurol Sci. 2023 Aug;44(8):2981-2982. doi: 10.1007/s10072-023-06796-8. Epub 2023 Apr 11.

DOI:10.1007/s10072-023-06796-8

PMID:37041395

Abstract

摘要

相似文献

Interleukin-17 inhibitors in myasthenia gravis: really bad or maybe good?

Neurol Sci. 2023 Aug;44(8):2981-2982. doi: 10.1007/s10072-023-06796-8. Epub 2023 Apr 11.

Myasthenia gravis associated with muscle-specific kinase antibodies in a patient treated with interleukin-17 inhibitor.

Neurol Sci. 2023 Mar;44(3):1105-1107. doi: 10.1007/s10072-022-06498-7. Epub 2022 Nov 11.

Myasthenia gravis: myasthenia vs. cholinergic crisis.

Pediatr Emerg Care. 2005 Aug;21(8):546-8; quiz 549-51. doi: 10.1097/01.pec.0000173353.76142.81.

Management of juvenile myasthenia gravis.

Pediatr Neurol. 2013 Feb;48(2):95-104. doi: 10.1016/j.pediatrneurol.2012.07.008.

Cholinesterase inhibitors in myasthenia gravis.

Practitioner. 1966 Mar;196(173):448-53.

The management of myasthenia gravis.

Acta Med Philipp. 1966 Jan-Mar;2(3):157-8.

Treatment of myasthenia gravis.

Mayo Clin Proc. 1983 Dec;58(12):842.

Management of myasthenia gravis.

J Assoc Physicians India. 1991 Aug;39(8):655.

Anticholinergics in myasthenia gravis.

J Assoc Physicians India. 1992 Aug;40(8):556-7.

Myasthenia gravis. Emergency treatment.

Minn Med. 1968 Sep;51(9):1291-3.

引用本文的文献

Response to Letter to the Editor by Kim et al.

Neurol Sci. 2023 Dec;44(12):4535. doi: 10.1007/s10072-023-06989-1. Epub 2023 Aug 3.

本文引用的文献

Myasthenia gravis associated with muscle-specific kinase antibodies in a patient treated with interleukin-17 inhibitor.

Neurol Sci. 2023 Mar;44(3):1105-1107. doi: 10.1007/s10072-022-06498-7. Epub 2022 Nov 11.

Paradoxical Reactions to Biologicals in Chronic Inflammatory Systemic Diseases.

Dtsch Arztebl Int. 2022 Feb 11;119(6):88-95. doi: 10.3238/arztebl.m2022.0067.

Immunotherapy in myasthenia gravis in the era of biologics.

Nat Rev Neurol. 2019 Feb;15(2):113-124. doi: 10.1038/s41582-018-0110-z.

Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature.

Actas Dermosifiliogr (Engl Ed). 2018 Nov;109(9):791-800. doi: 10.1016/j.ad.2018.04.003. Epub 2018 Jun 11.

Neurological and psychiatric disorders in psoriasis.

Rev Neurosci. 2018 Sep 25;29(7):805-813. doi: 10.1515/revneuro-2017-0108.

Current knowledge on psoriasis and autoimmune diseases.

Psoriasis (Auckl). 2016 Feb 22;6:7-32. doi: 10.2147/PTT.S64950. eCollection 2016.

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90. doi: 10.1111/jdv.12751. Epub 2014 Sep 22.

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).

Br J Dermatol. 2015 Feb;172(2):484-93. doi: 10.1111/bjd.13348. Epub 2014 Dec 11.

Secukinumab in plaque psoriasis--results of two phase 3 trials.

N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.

Three cases of psoriasis vulgaris associated with myasthenia gravis.

J Dermatol. 2014 May;41(5):462-3. doi: 10.1111/1346-8138.12456.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Interleukin-17 inhibitors in myasthenia gravis: really bad or maybe good?

Neurol Sci. 2023 Aug;44(8):2981-2982. doi: 10.1007/s10072-023-06796-8. Epub 2023 Apr 11.

Myasthenia gravis associated with muscle-specific kinase antibodies in a patient treated with interleukin-17 inhibitor.

Neurol Sci. 2023 Mar;44(3):1105-1107. doi: 10.1007/s10072-022-06498-7. Epub 2022 Nov 11.

Myasthenia gravis: myasthenia vs. cholinergic crisis.

Pediatr Emerg Care. 2005 Aug;21(8):546-8; quiz 549-51. doi: 10.1097/01.pec.0000173353.76142.81.

Management of juvenile myasthenia gravis.

Pediatr Neurol. 2013 Feb;48(2):95-104. doi: 10.1016/j.pediatrneurol.2012.07.008.

Cholinesterase inhibitors in myasthenia gravis.

Practitioner. 1966 Mar;196(173):448-53.

The management of myasthenia gravis.

Acta Med Philipp. 1966 Jan-Mar;2(3):157-8.

Treatment of myasthenia gravis.

Mayo Clin Proc. 1983 Dec;58(12):842.

Management of myasthenia gravis.

J Assoc Physicians India. 1991 Aug;39(8):655.

Anticholinergics in myasthenia gravis.

J Assoc Physicians India. 1992 Aug;40(8):556-7.

Myasthenia gravis. Emergency treatment.

Minn Med. 1968 Sep;51(9):1291-3.

引用本文的文献

Response to Letter to the Editor by Kim et al.

Neurol Sci. 2023 Dec;44(12):4535. doi: 10.1007/s10072-023-06989-1. Epub 2023 Aug 3.

本文引用的文献

Myasthenia gravis associated with muscle-specific kinase antibodies in a patient treated with interleukin-17 inhibitor.

Neurol Sci. 2023 Mar;44(3):1105-1107. doi: 10.1007/s10072-022-06498-7. Epub 2022 Nov 11.

Paradoxical Reactions to Biologicals in Chronic Inflammatory Systemic Diseases.

Dtsch Arztebl Int. 2022 Feb 11;119(6):88-95. doi: 10.3238/arztebl.m2022.0067.

Immunotherapy in myasthenia gravis in the era of biologics.

Nat Rev Neurol. 2019 Feb;15(2):113-124. doi: 10.1038/s41582-018-0110-z.

Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature.

Actas Dermosifiliogr (Engl Ed). 2018 Nov;109(9):791-800. doi: 10.1016/j.ad.2018.04.003. Epub 2018 Jun 11.

Neurological and psychiatric disorders in psoriasis.

Rev Neurosci. 2018 Sep 25;29(7):805-813. doi: 10.1515/revneuro-2017-0108.

Current knowledge on psoriasis and autoimmune diseases.

Psoriasis (Auckl). 2016 Feb 22;6:7-32. doi: 10.2147/PTT.S64950. eCollection 2016.

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90. doi: 10.1111/jdv.12751. Epub 2014 Sep 22.

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).

Br J Dermatol. 2015 Feb;172(2):484-93. doi: 10.1111/bjd.13348. Epub 2014 Dec 11.

Secukinumab in plaque psoriasis--results of two phase 3 trials.

N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.

Three cases of psoriasis vulgaris associated with myasthenia gravis.

J Dermatol. 2014 May;41(5):462-3. doi: 10.1111/1346-8138.12456.